Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Captainblkon Dec 20, 2019 2:47pm

31 Views

Post# 30477820

RE:Extremely Disappointing to see a Fustrated shorter

Captainblk wrote: make a new profile every day to try and discredit a company with a life saving product. think about that for a second- this person is either so bitter they are trying to see this company fail, or trying to slander it for their own financial gain. where everyone else says f^ck cancer, they are cheering it on

TobyTobias4000

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?